Tag Archives: ChromaCode

January 2020—ChromaCode has launched the HDPCR Multi-Drug Resistance (MDR) Panel, a highly multiplexed real-time PCR assay. The panel detects nine of the most common causes of Gram-negative multidrug resistance and toxigenic Clostridium difficile in a 96-well format. Key features of the panel, the company reports, include seamless integration onto common qPCR instrumentation, scalable throughput, and streamlined data analysis, management, and test customization with ChromaCode Cloud software. The MDR panel is for research use only.

November 2019—ChromaCode announced publication of a study by the Medical College of Wisconsin, Milwaukee, and Gundersen Medical Foundation, La Crosse, Wis., highlighting the performance and utility of the High-Definition PCR Tick-Borne Pathogen Panel RUO.

February 2019—ChromaCode announced the commercial launch of its first multiplex test using the company’s proprietary high-definition polymerase chain reaction technology.

July 2018—ChromaCode announced the publication of studies from Dartmouth-Hitchcock Medical Center and USC’s Keck School of Medicine highlighting the utility of the company’s HDPCR chemistry and the performance of the HDPCR respiratory assay, for research use only.